Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Mr. Nazmul Hassan

Market Cap

490.01 Million GBp

Sector

Healthcare

Website

https://www.beximcopharma.com

Description

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh.

Read More

Overview

Value

24

Growth

53

Health

31

Management

13

Analyst Opinion

71

Total

38

All Scores Out Of 100

Best Features

  • Has a low level of debt
  • Has a history of share buybacks
  • Price-to-earnings ratio of 5.1 is lower than the market average (19.6x)
  • Liked by analysts
  • 0

Risk Factors

  • Earnings have declined recently
  • No margin of safety at their current market price

Market Peers

BXP.L

Key Figures

PE Ratio (TTM)

5.13

Margin Of Safety (DCF)

-98.69%

Revenue Growth (5 Year Average)

15.03%

Ratings Consensus

Buy

Share Buybacks

0.01%

Dividend Yeild (TTM)

0.03%

Valuation

Value Score

24

  • Price-to-earnings ratio of 5.1 is lower than the market average (19.6x)
  • Estimated intrinsic-value of 641.35 undefined GBp is lower than current price ( 50.00 GBp)
  • Free-cashflow-yeild of 0.02% is worse than the market average (4.7%)
  • Margin-of-safety of -98.69% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: < 9.2 GBp

Current Price: 49 GBp

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

5.13x

Free Cashflow Yeild

0.02%

PE/Earnings Growth

N/A

Price/Book

104.29x

Growth

Growth Score

53

  • 5 Year Average Revenue growth of 15.03% is higher than the market average (10.97%)
  • 5 Year Average Earnings growth of 15.94% is higher than the market average (14.48%)
  • Revenue growth has slowed this year
  • Earnings growth has slowed this year
  • 5 Year Average Free Cashflow growth of 6.05% is lower than the market average (12.35%)
  • Free Cashflow growth has slowed this year

Revenue Growth

15.03%

Earnings Growth

15.94%

Cashflow Growth

6.05%

Health

Health Score

31

  • Has a low level of debt
  • Assets cover liabilities
  • Normal operation does not require debt to be sustainable
  • Debt repayments significantly impact cashflow

Altman Z Score

1.61

Piostroski Score

4.00

Debt/Equity

N/Ax

Current Assets/Liabilities

1.60x

Free Cashflow/Total Debt

N/Ax

Debt/Capital

0.67x

Management

Management Score

13

  • Has a history of returning value to shareholders through stock buybacks
  • Has returned higher dividends when earnings have risen
  • Return-on-capital-employed of N/A is lower than the market average (10%)
  • Has repurchased shares when overvalued
  • Return-on-equity of N/A is lower than the market average (15%)

Average Buybacks/Dilution

0.01%

Recent Buybacks/Dilution

N/A

5 Year Price Volitility

38.70%

Return On Assets

N/A

Return On Capital Employed

N/A

Return On Equity

N/A

Return On Free Cashflow

N/A

Return On Investments

N/A

Analysts

Analyst Opinion

71

  • Ratings consensus is Buy

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Beximco Pharmaceuticals Limited

Currency

GBp

Beta

0.755989

Vol Avg

49433

Ceo

Mr. Nazmul Hassan

Cik

Cusip

Exchange

London Stock Exchange

Full Time Employees

5500

Industry

Drug Manufacturers—Specialty & Generic

Sector

Healthcare

Ipo Date

2020-12-15

Address

19 Dhanmondi R/A

City

Dhaka

State

Country

BD

Zip

1205

Phone

880 2 5861 1001

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies